Citation Report
List of articles citing

Hydroxychloroquine Blood Levels Predict Hydroxychloroquine Retinopathy

DOI: 10.1002/art.41121
Arthritis and Rheumatology, 2020, 72, 448-453.

Source: https://exaly.com/paper-pdf/75018812/citation-report.pdf
Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
75	Update on antimalarials and systemic lupus erythematosus. *Current Opinion in Rheumatology*, **2020**, 32, 572-582	5.3	6
74	Reducing lupus flares: should we be more careful about stopping glucocorticoids?. *Expert Review of Clinical Immunology*, **2020**, 16, 539-542	5.1	1
73	[Therapeutic de-escalation in systemic lupus erythematosus in remission]. *Revue De Medecine Interne*, **2020**, 41, 795-799	0.1	0
72	The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse. *Infectious Diseases and Therapy*, **2020**, 9, 561-572	6.2	15
71	Do Hydroxychloroquine Blood Levels and Dose Identify Different Populations at Risk of Retinopathy? Comment on the Article by Petri et al. *Arthritis and Rheumatology*, **2020**, 72, 2165-2166	9.5	
70	RheumatologistsTperspective on hydroxychloroquine guidelines. *Lupus Science and Medicine*, **2020**, 7,	4.6	1
69	Measurement of hydroxychloroquine in blood from SLE patients using LC-HRMS-evaluation of whole blood, plasma, and serum as sample matrices. *Arthritis Research and Therapy*, **2020**, 22, 125	5.7	13
68	Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. *Annals of the Rheumatic Diseases*, **2020**, 79, 1386-1388	2.4	56
67	Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. *Advances in Rheumatology*, **2020**, 60, 32	3	24
66	Rethinking the Hydroxychloroquine Dosing and Retinopathy Screening Guidelines. *American Journal of Ophthalmology*, **2020**, 219, 101-106	4.9	7
65	Treatment of cutaneous lupus erythematosus: current approaches and future strategies. *Current Opinion in Rheumatology*, **2020**, 32, 208-214	5.3	4
64	Kidney outcomes for children with lupus nephritis. *Pediatric Nephrology*, **2021**, 36, 1377-1385	3.2	16
63	Different Control Populations May Lead to Different Understanding of Hydroxychloroquine Blood Levels as a Risk Factor for Retinopathy: Comment on the Article by Petri et al. *Arthritis and Rheumatology*, **2021**, 73, 715	9.5	1
62	Reply to Comment on: Rethinking the Hydroxychloroquine Dosing and Retinopathy Screening Guidelines. *American Journal of Ophthalmology*, **2021**, 222, 400-401	4.9	
61	Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study. *Clinical Microbiology and Infection*, **2021**, 27, 611-617	9.5	12
60	Early-Onset Hydroxychloroquine Retinopathy and a Possible Relationship to Blood Levels: Comment on the Article by Petri et al. *Arthritis and Rheumatology*, **2021**, 73, 358-359	9.5	2
59	The influence of obesity on hydroxychloroquine blood levels in lupus nephritis patients. *Lupus*, **2021**, 30, 554-559	2.6	3

58	Hydroxychloroquine and SARS-CoV-2 (COVID-19): An Old Problem and New Considerations in Ophthalmology. *Open Ophthalmology Journal*, **2021**, 14, 78-81	0.9	
57	Prescription strategy of antimalarials in cutaneous and systemic lupus erythematosus: an international survey. *Therapeutic Advances in Musculoskeletal Disease*, **2021**, 13, 1759720X211002595	3.8	2
56	Hydroxychloroquine blood levels in stable lupus nephritis under low dose (2-3 mg/kg/day): 12-month prospective randomized controlled trial. *Clinical Rheumatology*, **2021**, 40, 2745-2751	3.9	2
55	Accuracy of self-reported risk factors for hydroxychloroquine retinopathy. *Canadian Journal of Ophthalmology*, **2021**,	1.4	
54	One-year prospective nerve conduction study of thalidomide neuropathy in lupus erythematosus: Incidence, coasting effect and drug plasma levels. *Lupus*, **2021**, 30, 956-964	2.6	1
53	Does therapeutic drug monitoring of hydroxychloroquine improve treatment outcome in intensive care unit patients with COVID-19?. *International Journal of Clinical Practice*, **2021**, 75, e13894	2.9	0
52	American College of Rheumatology, American Academy of Dermatology, Rheumatologic Dermatology Society, and American Academy of Ophthalmology 2020 Joint Statement on Hydroxychloroquine Use With Respect to Retinal Toxicity. *Arthritis and Rheumatology*, **2021**, 73, 908-911	9.5	10
51	Systemic toxicity of chloroquine and hydroxychloroquine: prevalence, mechanisms, risk factors, prognostic and screening possibilities. *Rheumatology International*, **2021**, 41, 1189-1202	3.6	5
50	Ocular findings in Japanese patients with hydroxychloroquine retinopathy developing within 3 ́years of treatment. *Japanese Journal of Ophthalmology*, **2021**, 65, 472-481	2.6	2
49	Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus. *Arthritis and Rheumatology*, **2021**, 73, 997-1004	9.5	7
48	Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?. *Joint Bone Spine*, **2021**, 88, 105143	2.9	4
47	Adult systemic lupus erythematosus in Egypt: The nation-wide spectrum of 3661 patients and world-wide standpoint. *Lupus*, **2021**, 30, 1526-1535	2.6	16
46	Frequency and risk factors for hydroxychloroquine retinopathy among patients with systemic lupus erythematosus. *The Egyptian Journal of Internal Medicine*, **2021**, 33, 18	0.5	
45	Prescribing Patterns of Hydroxychloroquine and Corticosteroids Among Lupus Patients After New-onset End-stage Renal Disease. *Arthritis Care and Research*, **2021**,	4.7	0
44	Effect of Pantoprazole on the Absorption of Hydroxychloroquinea A Randomized Drug-Drug Interaction Trial in Healthy Adults. *Clinical Pharmacology in Drug Development*, **2021**,	2.3	0
43	Systemic lupus erythematosus: a clinical update. *Internal Medicine Journal*, **2021**, 51, 1219-1228	1.6	1
42	Reply. *Arthritis Care and Research*, **2021**,	4.7	
41	Clinically effective concentration and risk of hydroxychloroquine retinopathy in systemic lupus erythematosus: walking on a thin line. Comment on the article by Garg et al. *Arthritis Care and Research*, **2021**,	4.7	

40	Autoantibodies Against Unmodified and Citrullinated Human Endogenous Retrovirus K Envelope Protein in Patients With Rheumatoid Arthritis. *Journal of Rheumatology*, **2021**,	4.1	0
39	More Steps Forward to Optimize the Dosing of Hydroxychloroquine: Comment on the Article by Petri et al. *Arthritis and Rheumatology*, **2021**, 73, 2149	9.5	1
38	Risk versus Benefit of Using Hydroxychloroquine to Treat Patients with COVID-19. *Canadian Journal of Infectious Diseases and Medical Microbiology*, **2021**, 2021, 5942366	2.6	2
37	Reply. *Arthritis and Rheumatology*, **2021**, 73, 2149-2150	9.5	1
36	Hydroxychloroquine dans les maladies syst□miques et auto-immunes : o□en sommes-nous ?. *Revue Du Rhumatisme (Edition Francaise)*, **2021**, 88, 346-353	0.1	
35	Antimalarial drugs (and lupus). **2021**, 601-609		
34	Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis. *Rheumatology*, **2020**, 59, 3807-3816	3.9	10
33	Validation of a liquid chromatography tandem mass spectrometry method for the simultaneous determination of hydroxychloroquine and metabolites in human whole blood. *Clinical Chemistry and Laboratory Medicine*, **2020**, 58, 2047-2061	5.9	4
32	Chloroquine and Hydroxychloroquine Toxicity. *American Journal of Ophthalmic Clinical Trials*, 2, 8	3	3
31	The influence of bitter-taste receptor (TAS2R) expression in pharmacological response to Chloroquine in obese patients with COVID-19. *Clinics*, **2020**, 75, e2181	2.3	1
30	American College of Rheumatology White Paper on Antimalarial Cardiac Toxicity. *Arthritis and Rheumatology*, **2021**, 73, 2151-2160	9.5	2
29	Review on the Clinical Pharmacology of Hydroxychloroquine Sulfate for the Treatment of COVID-19. *Current Drug Metabolism*, **2020**, 21, 427-435	3.5	1
28	Risk of hydroxychloroquine retinopathy in the community. *Rheumatology*, **2021**,	3.9	0
27	New Insights Into Systemic Lupus Erythematosus Therapies: 2010-2020. *Journal of Clinical Rheumatology*, **2020**,	1.1	1
26	Hydroxychloroquine administration exacerbates acute kidney injury complicated by lupus nephritis.. *Arthritis Research and Therapy*, **2022**, 24, 6	5.7	0
25	Hydroxychloroquine and lupus flare: a good drug, but we need to do better.. *Annals of the Rheumatic Diseases*, **2022**,	2.4	0
24	Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge.. *Therapeutic Advances in Musculoskeletal Disease*, **2022**, 14, 1759720X211073001	3.8	5
23	COVID-19 Pandemic: current Challenges and future Perspectives. *Research Journal of Pharmacy and Technology*, **2022**, 329-337	1.7	3

22	Prevalence of ECG testing and characteristics among new hydroxychloroquine and chloroquine users within a multi-center tertiary care center.. *Rheumatology International*, **2022**, 1	3.6	
21	Advances in the clinical use of hydroxychloroquine levels.. *Current Opinion in Rheumatology*, **2022**, 34, 151-157	5.3	0
20	Influence of hydroxychloroquine blood levels on adhesion molecules associated with endothelial dysfunction in patients with systemic lupus erythematosus.. *Lupus Science and Medicine*, **2022**, 9,	4.6	
19	Hydroxychloroquine Blood Concentrations Can Be Clinically Relevant Also After Drug Discontinuation.. *Drugs in R and D*, **2022**,	3.4	0
18	Rapid Macular Thinning is an Early Indicator of Hydroxychloroquine Retinal Toxicity.. *Ophthalmology*, **2022**,	7.3	0
17	Drug monitoring in systemic lupus erythematosus.. *Current Opinion in Pharmacology*, **2022**, 64, 102225	5.1	
16	Automated Machine Learning Detection of Hydroxychloroquine Toxicity and Prediction of Future Toxicity Using Higher Order OCT Biomarkers. *Ophthalmology Retina*, **2022**,	3.8	1
15	Screening for Plaquenil. *Advances in Ophthalmology and Optometry*, **2022**,	0.5	
14	Systemic Lupus Erythematosus: New Diagnostic and Therapeutic Approaches. *Annual Review of Medicine*, **2023**, 74,	17.4	1
13	Compliance With Hydroxychloroquine Screening Guidelines at a Large Academic Medical Center. *Journal of Vitreoretinal Diseases*, 247412642210978	0.7	
12	How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.		0
11	Rapid Onset and Resolution of Hydroxychloroquine Cardiomyopathy: A Case Report. **2022**, 2022, 1-4		0
10	Pharmacokinetics of hydroxychloroquine in Japanese systemic lupus erythematosus patients with renal impairment.		0
9	Characteristics and Potential Risk Factors of Hydroxychloroquine Retinopathy in Patients with Systemic Lupus Erythematosus: Focusing on Asian Population.		0
8	Retinal toxicity in a multinational inception cohort of patients with systemic lupus on hydroxychloroquine. **2022**, 9, e000789		0
7	Hydroxychloroquine repairs burn damage through the Wnt/Ecatenin pathway. **2022**, 110309		0
6	Skin and ophthalmic complications of chloroquine and hydroxychloroquine in patients with rheumatoid arthritis and systemic lupus erythematous.		0
5	Hydroxychloroquine Dose and Risk for Incident Retinopathy.		0

4	Hydroxychloroquine impairs mTORC1-dependent cholesterol biosynthesis and sensitizes retinal pigment epithelial cells to UV-induced cell death..	0
3	Systemic Lupus Erythematosus. **2023**, 167-212	0
2	Systemic Lupus Erythematosus May Be a Risk Factor for Antimalarial-Induced Retinopathy Compared With Other Rheumatologic Diseases. **2023**, 5, 173-179	0
1	Low estimated glomerular filtration rate is an independent risk factor for higher hydroxychloroquine concentration.	0